Clinical trial NCT01167257: Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome
Official title: Comparative Study of the Efficacy and Safety of Liposome Encapsulated Botulinum Toxin-A (Lipotoxin) Versus Normal Saline Instillation in Treatment of Patients With Refractory Overactive Bladder Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Overactive Bladder
Keywords: Overactive bladder
Detrusor overactivity
Liposome
Botulinum toxin A
Lead sponsor: Buddhist Tzu Chi General Hospital
Sponsor class: OTHER
First posted: 2010-07-22
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Overactive bladder (OAB) is a bothered symptom syndrome. Traditional medication for OAB is antimuscarinic agent. However, adverse events such as dry mouth, constipation, blurred vision, and dizziness may prohibit patient to take this drug for OAB. Intravesical botulinum toxin A (BoNT-A) is a novel treatment however, BoNT-A can cause acute urinary retention and large postvoid residual. In this grant we will evaluate liquid liposome delivery of BoNT-A (Liposome encapsulated BoNT-A) into the bladder without the need for cystoscopic-guided needle injection for refractory OAB.

Detailed description: Overactive bladder (OAB) is a symptom syndrome characterized by urgency frequency with or without urgency incontinence, usually no metabolic or anatomical disorders can be found and it may have great impact on quality of life. Traditional medication for OAB is antimuscarinic agent which targets at the muscarinic receptors. There are several adverse events such as dry mouth, constipation, blurred vision, and dizziness related to antimuscarinics, therefore, some patients cannot tolerated this treatment. Intravesical botulinum toxin A (BoNT-A) has recently emerged as novel treatment for OAB refractory to antimuscarinics, however, BoNT-A injection can cause acute urinary retention and large postvoid residual. Urinary tract infection usually occurred following large postvoid residual and urinary retention. If we can deliver BoNT-A through the urothelium to the suburothelial space, but not into the detrusor layer, we might have therapeutic effects on the urothelial sensory nerves without compromising the detrusor contractility. This treatment will enable us to prevent the undesired detrusor underactivity after BoNT-A injection, especially in the elderly patients who had impaired detrusor contractility and OAB. Liposomes are vesicles, composed of concentric phospholipid bilayers separated by aqueous compartments. Because liposomes adsorb to cell surfaces and fuse with cells, they are being used as vehicles for drug delivery and gene therapy. In this grant we will evaluate liquid liposome delivery of BoNT-A (Liposome encapsulated BoNT-A) into the bladder without the need for cystoscopic-guided needle injection for refractory OAB, and study the mechanism of action of intravesical liposomal drug delivery. If successful, we will leverage our technology transfer expertise and bring the science from the bench top to the bed side to apply for a physician sponsored Investigational New Drug (IND) trial using liposome-BoNT in patients with OAB or DO.

Eligibility criteria: Inclusion Criteria:

1. Adults with age of 20 years old or above
2. Patients with symptoms of urgency frequency and/or urge incontinence and a urgency severity scale (USS) of at least 2, with or without urodynamically proven detrusor overactivity (DO) (defined by the International Continence Society (ICS) recommendation as: spontaneous detrusor contraction occurring during bladder filling phase or occurring before uninhibited detrusor contraction voiding at bladder capacity in the urodynamic study)
3. Free of active urinary tract infection
4. Free of bladder outlet obstruction on enrollment
5. Free of overt neurogenic bladder dysfunction
6. Having been treated with antimuscarinic agents for at least 4 weeks without effect or with intolerable adverse effects
7. Patient has not been treated with bladder surgery for OAB, such as enterocystoplasty, that might affect the therapeutic effect of test drug
8. Patient can record voiding diary for the urinary frequency and urgency
9. Patient or his/her legally acceptable representative has signed the written informed consent form

Exclusion Criteria:

1. Use of antimuscarinic agent and effective in treatment of lower urinary tract symptoms
2. Patients with severe cardiopulmonary disease and such as congestive heart failure, arrhythmia, poorly controlled hypertension, not able to receive regular follow-up
3. Patients with bladder outlet obstruction on enrollment
4. Patients with postvoid residual \>150 mL
5. Patients with uncontrolled confirmed diagnosis of acute urinary tract infection
6. Patients have laboratory abnormalities at screening including:

   Alanine aminotransferase (ALT) \>3 x upper limit of normal range Aspartate aminotransferase (AST) \>3 x upper limit of normal range Patients have abnormal serum creatinine level \>2 x upper limit of normal range
7. Patients with any contraindication to be urethral catheterization during treatment
8. Female patients who is pregnant, lactating, or with child-bearing potential without contraception.
9. Myasthenia gravis, Eaton Lambert syndrome.
10. Patients with any other serious disease considered by the investigator not suitable for general anesthesia or in the condition to enter the trial
11. Patients participated investigational drug trial within 1 month before entering this study

Primary outcomes:
measure: Mean Change of the Total Frequency Per 3 Days
timeFrame: Baseline to 4 weeks after initial treatment
Secondary outcomes:
measure: Mean Change of the Urgency Episodes Per 3 Days
timeFrame: Baseline to 4 weeks after initial treatment
measure: Mean Change of the Urgency Urinary Incontinence (UUI) Per 3 Days
timeFrame: Baseline to 4 weeks after initial treatment
measure: Net Change of the Overactive Bladder Symptom Score (OABSS)
timeFrame: Baseline to 4 weeks after initial treatment
measure: Net Change of the Functional Bladder Capacity (FBC)
timeFrame: Baseline to 4 weeks after initial treatment
measure: Net Change of the Maximum Flow Rate (Qmax)
timeFrame: Baseline to 4 weeks after initial treatment
measure: Net Change of the Postvoid Residual Volume (PVR)
timeFrame: Baseline and 1 month after initial treatment
measure: Net Change of the Urgency Severity Score (USS) Within 3 Days
timeFrame: Baseline to 4 weeks after initial treatment
measure: Net Change of the Global Response Assessment (GRA)
timeFrame: Baseline to 4 weeks after initial treatment
Other outcomes:
Locations:
city: Hualien
country: Taiwan
facility: Buddhist Tzu Chi General Hospital
Study officials:
affiliation: Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University
name: Hann-Chorng Kuo, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Urology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
name: Yao-Chi Chuang, M.D.
role: PRINCIPAL_INVESTIGATOR
References: